NICE rec­om­mends Pfiz­er's mi­graine drug for use in the UK, with some re­stric­tions

The UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence (NICE) is rec­om­mend­ing Pfiz­er’s oral mi­graine drug rimegepant, known com­mer­cial­ly in the US as Nurtec and brand­ed in Eu­rope as Vy­du­ra. How­ev­er, there are a few re­stric­tions at play.

The pub­lic health body is rec­om­mend­ing the drug, orig­i­nal­ly made by Bio­Haven be­fore Pfiz­er’s $11.6 bil­lion ac­qui­si­tion of the com­pa­ny an­nounced last May — but on­ly for those with at least four mi­graine at­tacks a month, and no more than 15 in the same times­pan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.